Surgical therapy for drug-refractory ventricular tachycardia: results with mapping-guided subendocardial resection

Role of catheter and surgical ablation in congenital heart disease

The role of surgery and radiofrequency current ablation for the treatment of tachycardias in patients with congenital heart disease The use of radiofrequency current application as a treatment strategy has stimulated a revolution in our understanding of tachycardia mechanisms. The extension of its use to patients with congenital heart defects and tachyarrhythmias has opened the door to new treatments with known success rates and known risks for mortality and morbidity. Antiarrhythmic surgery aims to dissect or excavate a responsible substrate and is especially worth considering if cardiac surgery is being undertaken for other reasons. With suitable surgical skill and interest, and with strong electrophysiologic support, high success rates have been documented. Antiarrhythmic surgical incisions have the advantage of being visually controllable regarding the extent and location of damage to myocardial tissue. In other situations, radiofrequency current ablation is preferred because of its less-invasive character, its use of local anesthesia, and the avoidance of surgical trauma. Both surgery and catheter ablation require precise clarification of the tachycardia mechanism and precise localization of the underlying substrate. The importation of such techniques into the realm of open chest surgery would be difficult in light of the need for multiple intracardiac catheters and repeated fluoroscopically guided catheter positioning. Electrophysiologic studies performed during the antiarrhythmic surgical procedure cannot provide complete information, and their use is thus restricted to the arrhythmogenic myocardial target only [32,45]. In contrast, catheter-mediated electrophysiologic studies offer the option of exact diagnosis, precise substrate localization, and interventional treatment in a single session. Moreover, validation of the linear lesion's completeness has become a reliable predictor for mid- and long-term success in avoiding recurrences. As a result, the application of catheter-mediated ablation has exploded within the past 15 years. Antiarrhythmic surgery has survived as a discipline in a decreasing number of experienced hands [43,44]. As a result of recent experiences and modern technology, success rates above 90% [74-76, 81,88] for the interventional treatment of congenital tachycardias have become comparable to those reported in patients with "normal" hearts. For acquired tachycardias, acute success rates today range about 80% at the atrial level. The rate of recurrence is still relatively high at about 10-25% [73,76,77,79,91,96,102]. Further improvements are being pursued. Data on the treatment of acquired tachycardias at the ventricular level is largely anecdotal. Good early success rates are combined with a tendency to recurrence in longer-term follow-up [50,76,103-108]. Some of the late VT ablation recurrences may be explained by the fact that fibrotic, scarred, and hypertrophic myocardial tissue at the targeted site often prevents effective radiofrequency current application and lesion generation. In order to improve RF lesion depth and continuity, newly designed technologies for radiofrequency current ("cooled tip electrode", Cordis Webster, Baldwin Park, CA), and alternative energy sources (cryo-ablation, micro-wave, or ultrasound) are being readied for introduction in the very near future. For patients suffering from recurrent tachycardias and having other reasons for open-heart surgery, a hybrid concept can be created, utilizing modern 3-D electro-anatomical reconstruction as a basis for an electrophysiologically informed surgical procedure. Following such a concept, a hemodynamic catheterization can be combined with an electrophysiologic study to define critical myocardial zones for induced macro-re-entry tachycardias, or of those zones expected to play an arrhythmogenic role in the future. With such information, surgical incisions for cardiac access and repair can be planned and performed. The role of surgery in antiarrhythmic treatment can become preventive. Myocardial tissue is incised for cannulation and repair in a way that can reduce the chance of later scar-associated tachycardias [109]. The extension of surgical cuts to physiologic barriers of electrical conduction is a major strategy for the primary prevention of postsurgical or incisional arrhythmias. In addition, the simultaneous treatment at heart surgery of already existing tachycardias can be offered within the same session as a secondary preventive concept. Despite the immense growth of knowledge and experience in recent years, there is still a need for more knowledge about the factors causing arrhythmogenesis and their interactions. Prospective and randomized studies are needed to show the most effective strategies to prevent arrhythmia-mediated death. The future of antiarrhythmic treatment will less be directed by the limitations of current interventional tools, which will be improved, and more by an evolutionary process in philosophy regarding the understanding of arrhythmogenesis in these patients as the basis for new concepts of arrhythmia prevention and treatment.

Ventricular arrhythmias in the elderly

Sudden cardiac death (SCD) remains a significant medical problem in the United States. The incidence of SCD increases with advancing age because cardiovascular disease is more prevalent in the elderly. Management of ventricular arrhythmias in the elderly patient is especially challenging because of increased risk of interventional and pharmacologic therapies, altered pharmacokinetics of drugs, and sometimes unclear long-term benefits.

Can catheter ablation in cardiac arrest survivors prevent ventricular fibrillation recurrence?

Ventricular tachyarrhythmias are the most common cause for sudden cardiac death. The success of catheter ablation for supraventricular tachycardias led to the supposition that ablation could also be used in the treatment of ventricular tachycardias. Despite the promising results in bundle branch reentry and some forms of idiopathic ventricular tachycardia, the success rate in patients with coronary artery disease is still low. There is hope that new approaches to reliably localize the critical region of the tachycardia and new ablation techniques to create larger areas of injury may lead to a wider application of ablation therapy in the treatment of ventricular tachycardia. Survivors of cardiac arrest typically have more rapid and unstable arrhythmias than patients with sustained ventricular tachycardia, and these rapid arrhythmias frequently degenerate into ventricular fibrillation. The instability of the arrhythmia makes it impossible to localize the arrhythmia origin with current mapping techniques. Experimental and clinical data, however, suggest that these arrhythmias also frequently start from a localized area of electrical activation. With developments in mapping techniques and energy delivery, catheter ablation may soon become a feasible therapeutic approach in some patients with unstable arrhythmias. The article discusses the prerequisites for this approach and suggests the patients who may be appropriate candidates for this technique.

Perioperative and long-term results with mapping-guided subendocardial resection and left ventricular endoaneurysmorrhaphy

BACKGROUND

Surgical ablation of the arrhythmogenic focus in patients with life-threatening ventricular tachyarrhythmias can be curative. However, the surgical techniques have been plagued by a high perioperative mortality rate (averaging approximately 12%). Reconstruction of the left ventricle may reduce mortality.

METHODS AND RESULTS

Reconstruction of the left ventricle with a pericardial patch, or endoaneurysmorrhaphy, was performed with mapping-guided subendocardial resection for recurrent ventricular tachycardia in 25 patients over a 5-year period. Postoperatively, electrophysiological studies were conducted to assess the results of surgery, which were further evaluated during long-term follow-up with survival analyses. The study included 25 patients, 60 +/- 9 years of age, with coronary artery disease, discrete left ventricle aneurysms, and malignant ventricular tacharrhythmias. Left ventricular ejection fraction was 24 +/- 6% preoperatively. Left ventricular endocardial mapping, endocardial resection, and endoaneurysmorrhaphy were performed in all patients. There was no operative or postoperative (30-day) mortality. Postoperative ventricular tachycardia was induced in 2 of the 25 patients (8%); left ventricular function increased to 32 +/- 9% (range, 19% to 52%). At a mean follow-up of 37 +/- 16 months (range, 6 to 65 months), there had been 6 deaths, including 1 sudden cardiac death, 2 congestive heart failure deaths, and 3 noncardiac deaths. Analysis of multiple variables failed to identify predictors of postoperative inducibility, sudden cardiac death, cardiac death, or total mortality.

CONCLUSIONS

Endoaneurysmorrhaphy with a pericardial patch combined with mapping-guided subendocardial resection frequently cures recurrent ventricular tachycardia with low operative mortality and improvement of ventricular function. Long-term follow-up demonstrates low sudden cardiac death rates.

Ventricular tachycardia after myocardial infarction: from arrhythmia surgery to catheter ablation

Ventricular tachycardia due to prior myocardial infarction is caused by reentry. Intraoperative mapping at the time of arrhythmia surgery has shown that the reentry circuits are diverse in size and location. Many circuits are large, extending over several square centimeters. Endocardial excision guided by activation sequence mapping, fractionated sinus rhythm electrograms, or visual identification of scarred subendocardium renders 69% to 95% of patients free from inducible ventricular tachycardia, but with an operative mortality that exceeds 8% at most centers. Catheter ablation is difficult due to limitations of catheter mapping, relatively small size of lesions produced with current techniques, and limited access to intramural and epicardial portions of the reentry circuits. Many problems need to be overcome for catheter ablation to achieve success comparable to that of surgery. At present, only hemodynamically tolerated ventricular tachycardias can be mapped. Progress is being made, and it is likely that catheter ablation will become a viable therapy for subgroups of patients with postmyocardial infarction ventricular tachycardia.

Simultaneous 60-electrode mapping of ventricular tachycardia using percutaneous catheters

OBJECTIVES

We developed a new approach for mapping ventricular tachycardia at electrophysiologic study using simultaneous recordings from up to 60 catheter electrodes.

BACKGROUND

Good results for surgical or catheter ablation of ventricular tachycardia are limited by the ability to detect and completely map all of the underlying arrhythmogenic areas. Currently, catheter mapping of all configurations of ventricular tachycardia is impossible or unsatisfactory in at least 60% of patients because of poorly tolerated rapid rates, nonsustained ventricular tachycardia or multiple configurations.

METHODS

Twenty-four patients with recurrent ventricular tachycardia refractory to antiarrhythmic drugs were studied using up to six percutaneous decapolar catheters introduced into the ventricles. Left ventricular maps of ventricular tachycardia were achieved by two to three transseptal catheters, two to three transaortic catheters, a coronary sinus catheter and right ventricular catheters. Simultaneous endocardial maps of either right or left ventricles were possible with a resolution of approximately 1 to 2 cm. Up to 60 electrograms were digitized and recorded simultaneously using a custom-computerized mapping system.

RESULTS

Successful maps of 73 ventricular tachycardia configurations were obtained in 22 patients. The mapping procedure failed in two patients because of inability to catheterize the left ventricle in one and inability to induce monomorphic ventricular tachycardia in the other. The mean (+/- SD) ventricular tachycardia cycle length was 285 +/- 53 ms (range 215 to 470). A total of 39 separate arrhythmogenic areas (median 1, interquartile [25% to 75%] range 1 to 3/patient) were detected, of which 21 (54%) were in the left ventricular free wall, 17 (44%) were in the ventricular septum, and 1 (2%) was in the right ventricular outflow tract. Ten patients (45%) had at least two arrhythmogenic areas. Thirteen patients subsequently underwent operation. All but one of the arrhythmogenic areas found at surgical mapping had been identified at preoperative catheter mapping. Complications of the preoperative mapping procedure occurred in four patients, with complete resolution in three and minor long-term sequelae in the other.

CONCLUSIONS

This technique permits detailed catheter mapping of all types of monomorphic ventricular tachycardias, including those leading to hemodynamic collapse, and should enable better choice and direction of surgical or catheter ablation.

The effect of coronary bypass graft surgery for the prevention of sudden cardiac death: recurrent episodes after ICD implantation and review of literature

Sudden cardiac death (SCD) accounts for at least 50% of the mortality of patients with ischemic heart failure. Ventricular arrhythmias are responsible for most cases of sudden cardiac death. There is some evidence that coronary artery bypass graft (CABG) surgery may reduce the incidence of recurrent episodes of SCD by prevention of myocardial ischemia. To test the hypothesis that CABG surgery is effective in the prevention of SCD, we compared the recordings of implantable cardioverter defibrillators (ICD) in patients who underwent ICD implantation alone (n = 64) or ICD implantation and concomitant CABG surgery respectively (n = 11). All patients had experienced out of hospital cardiac arrest. ICD recordings were obtained every 3 months and the number of recurrent episodes of ventricular tachycardia (VT) for each time period was noted. Three months following ICD implantation patients in the surgically treated group had an average of one episode of VT per patient as compared to 2.7 episodes in the nonsurgical group. This difference was observed during the following months as well. However, at no time (up to 18 months of follow-up) this difference reached statistical significance. There were no deaths in the surgically treated group. Although we could not demonstrate a statistical significant difference between the two groups, there was a tendency in the surgically treated group to have less episodes of recurrent VT than in the medically treated group. We, therefore, conclude that survivors of SCD presenting with multivessel coronary artery disease (CAD) should undergo coronary artery bypass grafting to prevent myocardial ischemia as the triggering event for lethal ventricular arrhythmias.

Curative Therapy for Supraventricular Arrhythmia with Radiofrequency Catheter Ablation—Comparison with Surgical Therapy

Radiofrequency catheter ablation is a newly introduced technique that does not require open heart surgery and is designed for curing patients with arrhythmia. We present our experience with this technique in 223 patients, with recurrent supraventricular tachycardia due to accessory pathways associated with the Wolff-Parkinson-White syndrome or AV nodal reentrant tachycardia. Of the patients, 119 underwent radiofrequency ablation of accessory pathways, while 101 underwent AV nodal modification. Two patients underwent both AV nodal modification and accessory pathway ablation during the same session. One patient had AV nodal ablation. Mean age was 39.4 ± 14.1 years (13–73 years). There were 108 males and 115 females. Except for 1 patient, all had significant symptoms. Radiofrequency ablation performed during the first session was successful in 215 patients (96.4%). With repeat ablation, 218 (97.8%) of the patients were successfully ablated. When compared with surgery, the efficacy is similar; however, radiofrequency ablation is less costly and results in less morbidity. Radiofrequency catheter ablation is highly efficacious and is the treatment of choice in patients who are at risk for sudden death or have failed drug therapy. It should also be offered as an alternative to lifelong drug therapy.

Effects of coronary artery bypass grafting on ventricular arrhythmias: results with electrophysiological testing and long-term follow-up

Myocardial revascularization was performed in 56 patients with coronary artery disease who presented with ventricular tachycardia (VT) (n = 39) or ventricular fibrillation (n = 17). There were 46 men and 10 women, aged 65 +/- 10 years. Three vessel (n = 42) or left main disease (n = 4) was present in 82%. Left ventricular ejection fraction averaged 36% +/- 11%. Electrophysiological studies were performed preoperatively in all patients; 50 (89%) had inducible ventricular arrhythmias. Sustained monomorphic VT was induced in 40 patients (cycle length 284 +/- 61 msec). Reproducible symptomatic nonsustained VT was induced in four patients and ventricular fibrillation in six patients, while six patients had no inducible arrhythmia. Preoperatively the patients with inducible VT failed 3.3 +/- 1.2 drug trials during electrophysiological studies. In addition to coronary bypass, 22 patients also received an automatic implantable cardioverter defibrillator (ICD), 26 patients received prophylactic ICD patches, and 1 patient had resection of a false aneurysm. There were no perioperative deaths. Postoperative electrophysiological studies were performed in all 56 surgical survivors. Ventricular tachyarrhythmia could not be induced in the six patients who had no inducible VT preoperatively and in 13 of 40 (33%) with preoperatively inducible sustained VT or in 19 of 50 (38%) patients with any previously inducible ventricular arrhythmia, thus a total of 25 patients (45%) had no inducible VT postoperatively. Of the remaining, 11 patients were treated with antiarrhythmic drugs alone, 11 had already received an ICD (combined with drugs in 7), and another 9 received the ICD postoperatively (combined with drugs in 4).(ABSTRACT TRUNCATED AT 250 WORDS)

Ventricular tachycardia surgery in 1992: did the automatic defibrillator change this approach?

The role of ventricular tachycardia (VT) surgery has been changed since the automatic implantable cardioverter defibrillator (ICD) is available. We studied the follow-up of 131 patients who underwent mapping guided surgery due to recurrent VT refractory to antiarrhythmic drug treatment. There were 65 patients operated upon between 1980-1985 (group I) and 66 patients between 1986-1991 (group II). Ten patients (8%) died perioperatively (< 3 weeks after surgery) [7/65 patients, 11%, in group I and 3/66 patients, 5%, in group II (P = 0.15)]. During a mean follow-up of 41 +/- 24 months, 38 of 121 patients died (31%), significantly more patients in group I (24/58 patients, 41%) than in group II (14/63 patients, 22%) (P < 0.05). In group I, there was a higher incidence of sudden (7/58 patients, 12%) or cardiac death (15/58 patients, 26%) than in group II (sudden death 4/63 patients, 6%, cardiac death 7/63 patients, 11%) (P < 0.05). There was a similar incidence of VT recurrences between group I (9/65 patients, 14%) and group II (9/66 patients, 14%). Our data show that the indication for VT surgery has changed since the ICD is available because of better patient selection.

Predictors of surgical mortality and long-term results of endocardial resection for drug-refractory ventricular tachycardia

The results of surgical therapy performed in 51 consecutive patients with ventricular tachycardia were reviewed to determine short- and long-term predictors of success of such therapy in preventing recurrences of life-threatening ventricular arrhythmias. Of 41 patients (80%) who survived surgery, 40 had postoperative programmed stimulation and, of these patients, 78% (n = 31) had no inducible ventricular tachycardia on no antiarrhythmic therapy. This group had a very low incidence of arrhythmia recurrence, with only one nonfatal episode of ventricular tachycardia after a mean follow-up of 41 +/- 30 months. In contrast, two of the nine patients (22%) who had inducible arrhythmias postoperatively had cardiac arrest (p = 0.12). Multivariate analysis identified two significant predictors of perioperative mortality in our patients: increased duration of cardiopulmonary bypass time and increased baseline pulmonary capillary wedge pressure. It is concluded that (1) patients who do not have inducible ventricular tachycardia after arrhythmia surgery have a very low incidence of recurrent arrhythmia and (2) prolonged time of cardiopulmonary bypass and increased pulmonary capillary wedge pressure are predictive of perioperative mortality.

Role of mapping-guided surgery in patients with recurrent ventricular tachycardia

To assess the value of ventricular tachycardia (VT) surgery 108 patients with recurrent episodes of VT were studied. There were 97 patients with coronary artery disease (group I) and 11 patients without coronary artery disease (group II). All patients in group I underwent subendocardial resection; 12 patients also underwent cryoablation. Cryoablation alone was performed in all patients in group II. During a mean follow-up period of 40 +/- 27 months, 29 patients (30%) in group I and two patients (18%) in group II died (p = 0.33). There were nine patients (9%) in group I and six patients (55%) in group II who had nonfatal recurrences of VT after surgery (p less than 0.01). In group I, there was a higher mortality rate among patients who had VT of posterolateral origin (14 of 31 patients; 45%) compared with 3 of 11 patients (28%) who had VT of anterolateral origin, 1 of 8 patients (12%) who had VT of inferoseptal, and 11 of 39 (29%) patients who had VT of anteroseptal origin. None of the eight patients with two distinct origins of VT died.

Comparison of decremental and burst overdrive pacing as treatment for ventricular tachycardia associated with coronary artery disease

Several forms of antitachycardia pacing have been used successfully for terminating cardiac arrhythmias, and implantable devices now incorporate a tier of overdrive pacing for treating of ventricular tachycardia (VT). No consensus exists regarding the optimal mode of pacing therapy. Accordingly, a prospective, randomized, crossover study of antitachycardia pacing was performed to analyze the effects of 2 decremental forms (10 and 5 ms) and a synchronized burst overdrive pacing mode on episodes of VT. Overdrive antitachycardia pacing was an effective therapy (78%) for terminating VT. Burst overdrive pacing and an autodecremental pacing protocol, incorporating a 10 ms decrement, were found to be effective and comparable forms of therapy. Both of these pacing methods were superior in terminating VT when compared with a pacing scheme using a 5 ms coupling decrement (p less than 0.01). Tachycardia acceleration occurred in 6.4% of the episodes of VT. None of the pacing methods displayed a specific propensity for tachycardia acceleration, and no measure of tachycardia segments identified a predilection for pace terminability. Antitachycardia pacing is an effective therapy for VT and different pacing formulas have variable effects. Further, these effects appear to be independent of tachycardia cycle length and variability.

Surgical therapy for drug-refractory ventricular tachycardia: role of additional aneurysmectomy or bypass grafting

To assess whether additional aneurysmectomy and/or bypass grafting influence prognosis we studied 97 patients with recurrent sustained monomorphic ventricular tachycardia after an old myocardial infarction. All patients underwent subendocardial resection due to drug-refractory ventricular tachycardia. There were 41 patients who had resection alone, 27 patients had resection and aneurysmectomy, 13 patients had resection and bypass grafting and the remaining 16 patients had resection with both, aneurysmectomy and bypass grafting. During the mean follow-up of 40 +/- 27 months 29 patients died (30%) (total mortality), 7 patients suddenly (7%) and 20 patients from cardiac causes (20%). There were no significant differences in total mortality between patients with resection alone (32%), patients with resection and aneurysmectomy (22%), patients with resection and bypass grafting (31%) and patients who had resection, aneurysmectomy and bypass grafting (38%). In addition, no significant differences were observed in the incidence of sudden death and nonfatal recurrences between patients with resection alone: sudden death 12%, recurrences 7%; patients with resection and aneurysmectomy: sudden death 0%, recurrences 19%; patients with resection and bypass grafting: sudden death 0%, recurrences 8%; and patients with resection, aneurysmectomy and bypass grafting: sudden death 13%, recurrences 0%. Postoperatively, left ventricular function improved in 56% of patients who had resection and aneurysmectomy compared to 17% of patients with resection alone, 31% of patients with resection and bypass grafting and 19% of patients who had resection, aneurysmectomy and bypass grafting. There is a low risk of sudden death and nonfatal recurrences after subendocardial resection. An influence of additional surgical approaches (aneurysmectomy or bypass grafting) on prognosis is not visible.

Clinical experience in seventy-seven patients with the automatic implantable cardioverter defibrillator

Seventy-seven patients with drug-refractory sustained ventricular tachycardia (VT) (28 patients) or ventricular fibrillation (VF) (49 patients) underwent implantation of an automatic cardioverter defibrillator (AICD). The 67 men and 10 women, with a mean age of 60 +/- 12 years (range 18 to 79), had coronary artery disease (60 patients), idiopathic cardiomyopathy (eight patients), mitral valve prolapse (four patients), hypertensive heart disease (one patient), Ebstein's anomaly (one patient), long QT syndrome (one patient), and primary electrical disease (two patients). The mean left ventricular ejection fraction was 35 +/- 16% (range 10% to 75%). Sustained VT/VF was induced in 64 patients (83%) at baseline electrophysiologic testing. A mean of 4.1 +/- 1.3 antiarrhythmic drugs failed to control the arrhythmia. Associated surgery at AICD implantation included coronary artery bypass in 19 patients, coronary bypass with aneurysmectomy in six patients, and aneurysmectomy alone in one patient. Five patients had only prophylactic patches implanted during aneurysmectomy or coronary bypass and the AICD device was subsequently implanted under local anesthesia to prevent arrhythmia recurrence or to control persistently inducible VT. Operative mortality was 2.6% with two deaths from intractable VF. Fifty-two patients (69%) continued receiving antiarrhythmic drugs to suppress spontaneous VT. During a mean follow-up of 15 +/- 13 months (range 1 to 63), six patients died: two suddenly due to probable pulse generator failure (greater than 2 years old), one of acute myocardial infarction, two of heart failure, and one of respiratory failure.(ABSTRACT TRUNCATED AT 250 WORDS)